@article{3105675,
    title = "ERS/EAACI statement on severe exacerbations in asthma in adults: Facts, priorities and key research questions",
    author = "Bourdin, A. and Bjermer, L. and Brightling, C. and Brusselle, G.G. and Chanez, P. and Chung, K.F. and Custovic, A. and Diamant, Z. and Diver, S. and Djukanovic, R. and Hamerlijnck, D. and Horváth, I. and Johnston, S.L. and Kanniess, F. and Papadopoulos, N. and Papi, A. and Russell, R.J. and Ryan, D. and Samitas, K. and Tonia, T. and Zervas, E. and Gaga, M.",
    journal = "European Respiratory Journal",
    year = "2019",
    volume = "54",
    number = "3",
    publisher = "European Respiratory Society",
    issn = "0903-1936, 1399-3003",
    doi = "10.1183/13993003.00900-2019",
    keywords = "adult;  anxiety;  asthma;  disease exacerbation;  economics;  Europe;  female;  health care cost;  human;  male;  medical society;  medication compliance;  organization and management;  psychology;  pulmonology;  risk factor;  theoretical model, Adult;  Anxiety;  Asthma;  Disease Progression;  Europe;  Female;  Health Care Costs;  Humans;  Male;  Medication Adherence;  Models, Theoretical;  Pulmonary Medicine;  Risk Factors;  Societies, Medical",
    abstract = "Despite the use of effective medications to control asthma, severe exacerbations in asthma are still a major health risk and require urgent action on the part of the patient and physician to prevent serious outcomes such as hospitalisation or death. Moreover, severe exacerbations are associated with substantial healthcare costs and psychological burden, including anxiety and fear for patients and their families. The European Academy of Allergy and Clinical Immunology (EAACI) and the European Respiratory Society (ERS) set up a task force to search for a clear definition of severe exacerbations, and to also define research questions and priorities. The statement includes comments from patients who were members of the task force. Copyright © ERS 2019"
}